Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$3.23M$3.23M−29.2% vs Q2 2022 Net Income-$5.23M-$5.23MN/M vs Q2 2022 EPS Diluted-$0.03-$0.03N/M vs Q2 2022 Gross Profit$3,098,000−28.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,268,000N/M Free Cash Flowderived-$6,524,000N/M Margins · derivedGross margin96.1%+0.8 pt vs Q2 2022
Operating margin-155.8%−62.8 pt vs Q2 2022
Net margin-162.1%−13.6 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end